缬沙坦联合舒洛地特对糖尿病肾病的疗效观察

Effect of valsartan combined with sulodexide on diabetic nephropathy

目的观察缬沙坦联合舒洛地特对糖尿病肾病（DN）的疗效。方法将36例DN-Ⅲ期和36例DN～Ⅳ期患者随机分为三组：缬沙坦组、舒洛地特组、联合治疗组，每组12例，随访12周。比较治疗前后尿白蛋白排泄率（UAER）、24h尿蛋白定量、血肌酐、血脂、血浆白蛋白的变化。结果治疗12周后，DN一Ⅲ期三组UAER、DN-Ⅳ期24h尿蛋白定量均有下降，两期中缬沙坦组与舒洛地特组比较差异均无统计学意义（P〉0．05），而与联合治疗组比较差异均有统计学意义（p〈O．05）。结论缬沙坦联合舒洛地特能有效降低DN患者的屎蛋白．效果优干单一用药，

Objective To observe the effect of the combined therapy of valsartan and sulodexide on diabetic nephropathy（DN）. Methods Thirty-six patients with DN-m stage and thirty-six patients with DN-Ⅳ stage were randomized divided into valsartan group, sulodexide group, valsartan and sulodex ide group, each group had 12 patients. The follow-up was 12 weeks. Then the UAER, 24 h urinary pro tein, serum creatinine, blood lipid, plasma albumin were measured. Results After treatment of 12 weeks,the level of UAER of DN-Ⅲ stage and 24 h urinary protein of DN-Ⅳ stage decreased significantly in all the three groups, and no significant difference was observed between valsartan group and sulodexide group（P 〉 0. 05）in the two stages,but significant difference was noted compared with combined therapy group（P 〈 0. 05）. Conclusions Valsartan combined with sulodexide can effectively decrease the level of urine protein in patients with DN and the effect is better than single application.